Latest Depression News

BlueScope Steel reported a resilient $309 million underlying EBIT for 1H FY2025 despite depressed steel spreads, announcing a 30 cents per share interim dividend and extending its buy-back program. The company is targeting a $500 million incremental EBIT uplift by 2030 through cost initiatives and strategic growth projects.

BlueScope reported a $179 million net profit for 1H FY2025 amid challenging steel market conditions, while announcing a 30 cents per share dividend and a $240 million buy-back plan. The company is banking on cost initiatives and market recovery to boost earnings in the second half.

Amotiv Limited’s interim results reveal a 34.3% decline in net profit despite a 2.3% revenue increase, driven by significant impairments and restructuring costs. The company declared a fully franked interim dividend of 18.5 cents per share.

Actinogen Medical has published a peer-reviewed article confirming the efficacy of a 10 mg daily dose of Xanamem for treating neurological conditions, reinforcing its ongoing clinical trials in Alzheimer's and depression.

Red Hawk Mining has issued a supplementary target's statement endorsing FMG’s increased $1.20 per share takeover offer, with FMG now holding a commanding 78% stake. The directors urge shareholders to accept the offer ahead of the March 3 closing date, citing the absence of superior proposals.

Emyria reports sustained and statistically significant improvements in PTSD symptoms and quality of life three months after MDMA-assisted therapy, signaling a potential breakthrough for treatment-resistant patients.

Newfield Resources Limited reports a strategic pivot for its Tongo Diamond Mine, engaging a joint development partner to reduce costs and delay bulk sampling amid a depressed diamond market.

Sultan Resources reports steady progress in its Western Australia gold and Canadian lithium projects while pausing nickel drilling due to market conditions, supported by a recent capital raise.

Emyria Limited reports strong progress in its MDMA and psilocybin-assisted therapy programs alongside a successful $2.525 million capital raise, positioning the company for expanded mental health treatment services.

Reedy Lagoon Corporation reports promising soil sampling results at its Burracoppin Gold project while seeking partners for its iron venture amid challenging market conditions.

TrivarX has solidified its regulatory strategy for the pivotal MEB-001 trial with the FDA and unveiled a new algorithm that expands its mental health screening reach beyond sleep clinics.

Newfield Resources clarifies its $10 million loan facility status, postpones key sampling work, and updates on ongoing dispute with Octea Limited, signaling cautious navigation through financial and operational challenges.